| 翻訳と辞書 |
Liraglutide
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The product was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.〔http://www.drugs.com/nda/liraglutide_080530.html May 2008〕〔http://www.drugdevelopment-technology.com/projects/liraglutide/ "Liraglutide - Next-Generation Antidiabetic Medication"〕〔http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm198638.htm "FDA Approves New Treatment for Type 2 Diabetes" January 25, 2010〕 More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.
==Medical uses==
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Liraglutide」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|